The CHADS-VASc score is a predictor of no-reflow in patients with non-ST-segment elevation myocardial infarction


Barman H. A. , Kahyaoglu S., DURMAZ E. , Atici A., Gulsen K., Tugrul S., ...Daha Fazla

CORONARY ARTERY DISEASE, cilt.31, ss.7-12, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 31 Konu: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1097/mca.0000000000000781
  • Dergi Adı: CORONARY ARTERY DISEASE
  • Sayfa Sayıları: ss.7-12

Özet

This study was performed to evaluate the relationship between the CHA(2)DS(2)-VASc score and no-reflow (NR) phenomena in patients with non-ST-segment elevation myocardial infarction (NSTEMI). A total number of 428 consecutive patients with NSTEMI were assessed for this study. Patients were divided into 2 groups, those with NR, NR(+) (n=84), and those without NR, NR(-) (n=307), according to their post-PCI, no-reflow status. The CHA(2)DS(2)-VASc score was significantly higher in the NR(+) group compared to the NR(-) (3.48 +/- 1.19 vs 1.81 +/- 0.82,P< 0.001). After a multivariate regression analysis, a higher CHA(2)DS(2)-VASc score (OR: 6.52, 95% CI: 3.51-12.14,P< 0.001), hs-Troponin (OR: 1.077, 95% CI: 1.056-1.099,P<0.001) and TTG (OR: 1.563, 95% CI: 1.134-2.154,P=0.006) were independent predictors of NR. CHA(2)DS(2)-VASc score is associated with higher risk of no-reflow in patients with NSTEMI undergoing PCI.